[2] In 1965, Chong Kun Dang established the largest raw material pharmaceutical processing plant in Asia.

[2] On November 23, 2020, Chong Kun Dang announced it had acquired the Korean distribution rights to SkyLabs's heart-monitoring ring.

The deal, worth ₩2.5 billion (US$2.2 million), also granted Chong Kun Dang priority in negotiations for distribution rights in China, India, Japan, and the Middle East.

[3] On November 6, 2023, Chong Kun Dang agreed to a ₩1.7 trillion (US$1.3 billion) technology export contract with multinational corporation Novartis.

The contract granted Novartis the global distribution rights for Chong Kun Dang's CKD-510, a histone deacetylase inhibitor posited as a potential treatment for Charcot–Marie–Tooth disease.